 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 3 | 1/1 | 返回列表 |
| 查看: 479 | 回復(fù): 2 | ||
[交流]
As Pharma Jobs Leave N.J., Office Space Ghost Towns Remain 已有2人參與
|
|
Tom Stanton of the real estate firm Jones Lang LaSalle shows off empty lab space at Roche in Nutley, N.J. Daniel Tucker/WNYC roche-013ef156abac5f60e18756c3a4e0071c088c47be-s3-c85.jpg A Roche lab in 2009, a more bustling time. Mel Evans/AP New Jersey used to be known as "the nation's medicine chest," but over the past two decades, many of the state's pharmaceutical industry jobs have dried up or moved elsewhere, and left millions of square feet of office space, warehouses and laboratories sitting empty. One of those sites is the 116-acre corporate campus of the Swiss drugmaker Roche in Nutley, N.J. There are dozens of buildings on this campus, 10 miles west of midtown Manhattan. In fact, there are enough bio and chem labs, offices and auditoriums to fill up the entire Empire State Building. But since December, all of that space — 2 million square feet of it — has been vacant, the laboratories dark and the sidewalks deserted. "When this was a thriving site, this sidewalk would have been busy with folks walking up and down," says Darien Wilson, one of just 38 Roche employees still working at the site as the company tries to sell the property. "We had great amenities for people, like on-site child care. You had dinners to-go where you could order food by lunch and take it home with you if you were working late. We had dry cleaning," she says. Five years ago, Roche acquired Genentech, moved its management to San Francisco and started to slowly withdraw from New Jersey. That's a pretty typical story for what's been happening in the state. In the past 20 years, New Jersey went from having more than 20 percent of U.S. pharma manufacturing jobs to less than 10 percent. "Essentially, every time there's a merger or one company acquires another company, there's a reduction in force, and there's been furious mergers and acquisitions in the pharma industry, particularly over the past 10 years," says James Hughes, dean of the school of public policy at Rutgers. In 2009, Merck bought Schering-Plough, and Pfizer bought Wyeth. This year Pfizer tried to purchase the British drugmaker AstraZeneca. And the list goes on. Business professor Erik Gordon of the University of Michigan says cutting-edge research isn't being done on closed campuses in the suburbs anymore. "The new innovation in biotech, in genomics is happening elsewhere. It's happening in places where there are graduate educational institutions that have research faculty doing that, and New Jersey really doesn't have that," he says. That's something Roche is acutely aware of as it looks for a buyer. "What really sets this site apart is its location," says Tom Stanton of Jones Lang LaSalle, the real estate firm marketing the site. The site is so big that to show it off, Stanton needs a minibus. Looping through a parking lot with thousands of empty spaces, Stanton stresses how close the campus is to Manhattan, Newark's airport and public transit. "Hiring young, talented people is really important to these companies. And that population of upcoming talent is more into the city life," he says. But even though it's only a good bike ride from Manhattan in a straight line, the Roche campus can feel far away from the city's pulse. Stanton says finding even a single tenant has been difficult. So far, he's shown the campus to 35 companies, and no deal yet. The situation may be even worse for the Merck World Headquarters in Whitehouse Station, N.J. It's about 50 miles from Manhattan — making its 1 million square feet of space harder to fill. But there may be an answer. The state's biotech firms are growing fast, and they may be future tenants for these big pharma campuses. But so far, they've only been leasing small portions of space. Stanton says that could work for something like Roche's Building 123, a six-story structure with a lot of lab space. "That building [would] cost $600 million to re-create today," he says. Young companies would love to get some of its lab space. But they don't need, and can't afford, the whole building. Stanton just has to find a way to carve it up and then get some companies to bite. http://www.npr.org/2014/07/30/33 ... f=1001&ft=1 |
回復(fù)此樓
星海慧兒
榮譽版主 (職業(yè)作家)
木蟲精靈
- DRDEPI: 17
- 應(yīng)助: 849 (博后)
- 貴賓: 0.978
- 金幣: 22119.4
- 散金: 3714
- 紅花: 103
- 沙發(fā): 5
- 帖子: 3828
- 在線: 803.1小時
- 蟲號: 568253
- 注冊: 2008-06-03
- 專業(yè): 分析化學
- 管轄: 新藥研發(fā)
2樓2014-07-31 16:09:08
tang521095870
銀蟲 (知名作家)
- 應(yīng)助: 26 (小學生)
- 金幣: 544.8
- 散金: 6227
- 紅花: 56
- 沙發(fā): 26
- 帖子: 8781
- 在線: 657.3小時
- 蟲號: 524629
- 注冊: 2008-03-14
- 專業(yè): 中藥學
3樓2014-07-31 22:26:37
相關(guān)版塊跳轉(zhuǎn)
我要訂閱樓主 zhychen2008 的主題更新
| 3 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 材料專碩英一數(shù)二306 +6 | z1z2z3879 2026-03-18 | 6/300 |
|
|---|---|---|---|---|
|
|
[考研] 286分人工智能專業(yè)請求調(diào)劑愿意跨考！ +3 | lemonzzn 2026-03-17 | 3/150 |
|
|
|
[考研]
 320求調(diào)劑0856
+3
|
不想起名字112 2026-03-19 | 3/150 |
|
|
|
[考研] 化學求調(diào)劑 +3 | 臨澤境llllll 2026-03-17 | 4/200 |
|
|
|
[考研] 346求調(diào)劑[0856] +3 | WayneLim327 2026-03-16 | 6/300 |
|
|
|
[考研] 0703化學 305求調(diào)劑 +4 | FY_yy 2026-03-14 | 4/200 |
|
|
[考研] 311求調(diào)劑 +4 | 冬十三 2026-03-18 | 4/200 |
|
|
|
[考研] 295求調(diào)劑 +3 | 一志愿京區(qū)211 2026-03-18 | 5/250 |
|
|
|
[考研] 0854可跨調(diào)劑，一作一項核心論文五項專利，省、國級證書40+數(shù)一英一287 +8 | 小李0854 2026-03-16 | 8/400 |
|
|
|
[考研] 材料專碩306英一數(shù)二 +10 | z1z2z3879 2026-03-16 | 13/650 |
|
|
|
[考研] 302求調(diào)劑 +10 | 呼呼呼。。。。 2026-03-17 | 10/500 |
|
|
|
[考研] 工科材料085601 279求調(diào)劑 +6 | 困于星晨 2026-03-17 | 6/300 |
|
|
|
[考研] 環(huán)境工程調(diào)劑 +8 | 大可digkids 2026-03-16 | 8/400 |
|
|
|
[考研] 268求調(diào)劑 +6 | 簡單點0 2026-03-17 | 6/300 |
|
|
|
[考研] 考研調(diào)劑 +3 | 淇ya_~ 2026-03-17 | 5/250 |
|
|
|
[考研] 333求調(diào)劑 +3 | 文思客 2026-03-16 | 7/350 |
|
|
|
[考研] 0854控制工程 359求調(diào)劑 可跨專業(yè) +3 | 626776879 2026-03-14 | 9/450 |
|
|
|
[考研] 321求調(diào)劑 +5 | 大米飯！ 2026-03-15 | 5/250 |
|
|
|
[考研] 288求調(diào)劑 +4 | 奇點0314 2026-03-14 | 4/200 |
|
|
|
[考研] 289求調(diào)劑 +4 | 這么名字咋樣 2026-03-14 | 6/300 |
|